Skip to main content
OpenTrials
Completed

NCT Number: NCT04589104

Expressive Writing for COVID-19 Resilience

The purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the COVID-19 pandemic during spring 2020.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke Integrative Medicine

Durham, North Carolina, 27705, United States

About this study

The purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the COVID-19 pandemic during spring 2020.

Eligible subjects will be adults who are able to read and write in English and are cognitively able to provide informed consent. Potential subjects will be recruited through the Duke Health & Well-Being email lists. The entirely virtual 6-week expressive writing intervention will be delivered via Zoom, REDCap, and email, and subjects will complete measures at baseline, 6 weeks, and 10 weeks (1 month post-intervention). Each week of the intervention will invite participants to complete a series of expressive writing assignments designed to support emotional expression and cultivate resilience, and the assignments will take approximately 60-90 minutes each week to complete.

The primary outcome is the 25-item Connor-Davidson Resilience Scale (CD-RISC). Other measures will include a basic demographics survey, questions about COVID-19 impact, post-writing surveys collected after the writing assignments, the 10-item Perceived Stress Scale (PSS), the Center for Epidemiologic Studies Depression Scale-Revised, and the 21-item Post -Traumatic Growth Inventory (PTGI). Participants will also have the option to share the content of their writing assignments with the research team if they choose.

The risks of participation in this study are minimal and include the risk of mild sadness after the writing assignments and the risk of loss of confidentiality.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Potential subjects will be considered eligible if they feel they have been personally impacted by circumstances surrounding COVID-19. Other eligibility criteria include:

  • Able to speak, read, write, and understand English
  • Cognitively able to provide consent
  • Ability to participate in a 6-week intervention delivered via Zoom, REDCap, and email

Treatment and study plan

Expressive writing

Behavioral

The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:

  • Week 1: Writing to expressive difficult emotions
  • Week 2: Writing to release & integrate difficult emotions
  • Week 3: Writing to nurture gratitude
  • Week 4: Writing to enhance strengths & resources
  • Week 5: Writing to cultivate positive meaning & savor goodness
  • Week 6: Writing to invite insight, perspective, & growth

Primary outcomes

  1. Resilience

    Time frame: 3 months

    Connor-Davidson Resilience Scale (CD-RISC)

Secondary outcomes

  1. Perceived stress

    Time frame: 3 months

    Perceived Stress Scale-10 (PSS10)

  2. Depression symptoms

    Time frame: 3 months

    Center for Epidemiologic Studies Scale - Revised (CESDR)

  3. Post-traumatic growth

    Time frame: 3 months

    Post Traumatic Growth Inventory (PTGI)

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 19, 2020
Registry last updated
Oct 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.